Brief: Medicenna Presents Late Breaking Abstract Updating Results From Phase 2B Recurrent GBM Trial

Medicenna Therapeutics

26/10/2020 11:26

Oct 26 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PRESENTS LATE BREAKING ABSTRACT UPDATING RESULTS
FROM
PHASE 2B RECURRENT GBM TRIAL AT THE 36TH EORTC-NCI-AACR MEETING
    * MEDICENNA- AMONGST ALL-COMER POPULATION SINGLE TREATMENT
WITH
MDNA55 RESULTED IN ATLEAST 100%INCREASE IN12MONTH PROGRESSION
FREE SURVIVAL
    * MEDICENNA- AMONGST ALL-COMER POPULATION SINGLE TREATMENT
WITH
MDNA55 RESULTED IN ATLEAST 100%INCREASE IN 2-YEAR SURVIVAL(OS-24
OF 20% VERSUS 5 TO10%)
    * MEDICENNA-IN SUBSET OF ALLCOMER PATIENTS TREATED WITH
TRANSIENT
LOW DOSE BEVACIZUMAB,TO REDUCE STEROID USE,MEDIAN SURVIVAL WAS
21.8 MONTHS &OS-24 WAS 44%

Source text for Eikon:  ID:nGNX4d4FWZ 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))